Proteostasis files $86M IPO; Novartis publishes Cosentyx studies;

> Cambridge, MA-based Proteostasis Therapeutcs filed for an $86 million IPO. Filing

> Results of the MEASURE 1 and MEASURE 2 Phase III studies for Novartis's Cosentyx (secukinumab) in ankylosing spondylitis were published in The New England Journal of Medicine. Release

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.